Does Rallies show Form 4 insider transactions for OSCR?

Yes. Rallies tracks OSCR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OSCR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OSCR. It does not provide personalized investment advice.

OSCR (Oscar Health, Inc.) Stock Analysis - Insider Trades

Oscar Health, Inc. (OSCR) is a publicly traded Healthcare sector company. As of May 20, 2026, OSCR trades at $23.21 with a market cap of $7.63B and a P/E ratio of -48.75. OSCR moved -4.57% today. Year to date, OSCR is +41.34%; over the trailing twelve months it is +42.20%. Its 52-week range spans $10.69 to $25.58. Analyst consensus is neutral with an average price target of $17.43. Rallies surfaces OSCR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OSCR stock inside the company?

Recent OSCR insider activity includes Bertolini Mark T bought 1.00M, Liang Janet sold 7.45K, Baltrus Victoria sold 4.64K, McAnaney Adam sold 18.71K, and Schlosser Mario sold 24.34K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OSCR Key Metrics

Key financial metrics for OSCR
Metric	Value
Price	$23.21
Market Cap	$7.63B
P/E Ratio	-48.75
EPS	$-0.48
Dividend Yield	0.00%
52-Week High	$25.58
52-Week Low	$10.69
Volume	5.81M
Avg Volume	0
Revenue (TTM)	$13.30B
Net Income	$-39.39M
Gross Margin	0.00%

Recent OSCR Insider Trades

Bertolini Mark T bought 1.00M (~$11.92M) on Apr 6, 2026.
Liang Janet sold 7.45K (~$99.80K) on Mar 2, 2026.
Baltrus Victoria sold 4.64K (~$62.10K) on Mar 2, 2026.
McAnaney Adam sold 18.71K (~$250.53K) on Mar 2, 2026.
Schlosser Mario sold 24.34K (~$325.85K) on Mar 2, 2026.

Latest OSCR News

UBS Lifts Oscar Health Target to $20 After $679M Q1 Profit — May 7, 2026
Oscar Health jumps as Q1 2026 earnings approach and 2026 guidance stays intact — May 6, 2026
Oscar Health slides 3% as traders de-risk ahead of May 6 Q1 earnings — May 5, 2026
Oscar Health climbs ahead of May 6 Q1 report as insiders signal confidence — Apr 30, 2026
Oscar Health jumps as 2026 guidance reaffirmation keeps profitability narrative intact — Apr 28, 2026

OSCR Analyst Consensus

8 analysts cover OSCR: 0 strong buy, 0 buy, 6 hold, 2 sell, 0 strong sell. Consensus rating is neutral. Average price target: $17.43.

Common questions about OSCR

Who is trading OSCR stock inside the company?: Recent OSCR insider activity includes Bertolini Mark T bought 1.00M, Liang Janet sold 7.45K, Baltrus Victoria sold 4.64K, McAnaney Adam sold 18.71K, and Schlosser Mario sold 24.34K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OSCR?: Yes. Rallies tracks OSCR insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OSCR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OSCR. It does not provide personalized investment advice.